|
1
|
Ozpiskin OM, Zhang L and Li JJ: Immune
targets in the tumor microenvironment treated by radiotherapy.
Theranostics. 9:1215–1231. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Shi L, Wang X, Hu B, Wang D and Ren Z:
miR-222 enhances radiosensitivity of cancer cells by inhibiting the
expression of CD47. Int J Clin Exp Pathol. 12:4204–4213.
2019.PubMed/NCBI
|
|
3
|
Vermeer DW, Spanos WC, Vermeer PD, Bruns
AM, Lee KM and Lee JH: Radiation-induced loss of cell surface CD47
enhances immune-mediated clearance of human papillomavirus-positive
cancer. Int J Cancer. 133:120–129. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tong B and Wang M: CD47 is a novel potent
immunotherapy target in human malignancies: Current studies and
future promises. Future Oncol. 14:2179–2188. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang J, Jin S, Guo X and Qian W:
Targeting the CD47-SIRPα signaling axis: Current studies on B-cell
lymphoma immunotherapy. J Int Med Res. 46:4418–4426.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sun J, Muz B, Alhallak K, Markovic M,
Gurley S, Wang Z, Guenthner N, Wasden K, Fiala M, King J, et al:
Targeting CD47 as a novel immunotherapy for multiple myeloma.
Cancers (Basel). 12(305)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Miller TW, Soto-Pantoja DR, Schwartz AL,
Sipes JM, DeGraff WG, Ridnour LA, Wink DA and Roberts DD: CD47
receptor globally regulates metabolic pathways that control
resistance to ionizing radiation. J Biol Chem. 290:24858–24874.
2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Brooks SA and Blackshear PJ:
Tristetraprolin (TTP): Interactions with mRNA and proteins, and
current thoughts on mechanisms of action. Biochim Biophys Acta.
1829:666–679. 2013.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lee WH, Han MW, Kim SH, Seong D, An JH,
Chang HW, Kim SY, Kim SW and Lee JC: Tristetraprolin
posttranscriptionally downregulates TRAIL death receptors. Cells.
9(1851)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ross CR, Brennan-Laun SE and Wilson GM:
Tristetraprolin: Roles in cancer and senescence. Ageing Res Rev.
11:473–484. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sanduja S, Blanco FF, Young LE, Kaza V and
Dixon DA: The role of tristetraprolin in cancer and inflammation.
Front Biosci (Landmark Ed). 17:174–188. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
12
|
Park JM, Lee TH and Kang TH: Roles of
tristetraprolin in tumorigenesis. Int J Mol Sci.
19(3384)2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang D, Zhou Z, Yang R, Zhang S, Zhang B,
Tan Y, Chen L, Li T and Tu J: Tristetraprolin, a potential
safeguard against carcinoma: Role in the tumor microenvironment.
Front Oncol. 11(632189)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jiang W, Zhu D, Wang C and Zhu Y: Tumor
suppressing effects of tristetraprolin and its small
double-stranded RNAs in bladder cancer. Cancer Med. 10:269–285.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lee HH, Yang SS, Vo MT, Cho WJ, Lee BJ,
Leem SH, Lee SH, Cha HJ and Park JW: Tristetraprolin down-regulates
IL-23 expression in colon cancer cells. Mol Cells. 36:571–576.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Deng K, Wang H, Shan T, Chen Y, Zhou H,
Zhao Q and Xia J: Tristetraprolin inhibits gastric cancer
progression through suppression of IL-33. Sci Rep.
6(24505)2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang Q, Ning H, Peng H, Wei L, Hou R, Hoft
DF and Liu J: Tristetraprolin inhibits macrophage IL-27-induced
activation of antitumour cytotoxic T cell responses. Nat Commun.
8(867)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kim SH, Kang BC, Seong D, Lee WH, An JH,
Je HU, Cha HJ, Chang HW, Kim SY, Kim SW and Han MW: EPHA3
contributes to epigenetic suppression of PTEN in radioresistant
head and neck cancer. Biomolecules. 11(599)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kim SH, Lee WH, Kim SW, Je HU, Lee JC,
Chang HW, Kim YM, Kim K, Kim SY and Han MW: EphA3 maintains
radioresistance in head and neck cancers through epithelial
mesenchymal transition. Cell Signal. 47:122–130. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lee JC, Lee WH, Min YJ, Cha HJ, Han MW,
Chang HW, Kim SA, Choi SH, Kim SW and Kim SY: Development of TRAIL
resistance by radiation-induced hypermethylation of DR4 CpG island
in recurrent laryngeal squamous cell carcinoma. Int J Radiat Oncol
Biol Phys. 88:1203–1211. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tu Y, Wu X, Yu F, Dang J, Wang J, Wei Y,
Cai Z, Zhou Z, Liao W, Li L and Zhang Y: Tristetraprolin
specifically regulates the expression and alternative splicing of
immune response genes in HeLa cells. BMC Immunol.
20(13)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Betancur PA, Abraham BJ, Yiu YY,
Willingham SB, Khameneh F, Zarnegar M, Kuo AH, McKenna K, Kojima Y,
Leeper NJ, et al: A CD47-associated super-enhancer links
pro-inflammatory signalling to CD47 upregulation in breast cancer.
Nat Commun. 8(14802)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang H, Lu H, Xiang L, Bullen JW, Zhang
C, Samanta D, Gilkes DM, He J and Semenza GL: HIF-1 regulates CD47
expression in breast cancer cells to promote evasion of
phagocytosis and maintenance of cancer stem cells. Proc Natl Acad
Sci USA. 112:E6215–E6223. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu J, Xavy S, Mihardja S, Chen S,
Sompalli K, Feng D, Choi T, Agoram B, Majeti R, Weissman IL and
Volkmer JP: Targeting macrophage checkpoint inhibitor SIRPα for
anticancer therapy. JCI Insight. 5(e134728)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hendriks M, Ploeg EM, Koopmans I, Britsch
I, Ke X, Samplonius DF and Helfrich W: Bispecific antibody approach
for EGFR-directed blockade of the CD47-SIRPα ‘don't eat me’ immune
checkpoint promotes neutrophil-mediated trogoptosis and enhances
antigen cross-presentation. Oncoimmunology.
9(1824323)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Veillette A and Chen J: SIRPα-CD47 immune
checkpoint blockade in anticancer therapy. Trends Immunol.
39:173–184. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lakhani NJ, Chow LQM, Gainor JF, LoRusso
P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, et al:
Evorpacept alone and in combination with pembrolizumab or
trastuzumab in patients with advanced solid tumours (ASPEN-01): A
first-in-human, open-label, multicentre, phase 1 dose-escalation
and dose-expansion study. Lancet Oncol. 22:1740–1751.
2021.PubMed/NCBI View Article : Google Scholar
|
